James H. Powers

James H. Powers

Auto-generated profile, based on publicly available information

James H. Powers

Department of Psychiatry, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Ophthalmology Retina
Verified
Journal Article
Closed access
JPJames H. Powers
James H. Powers
ATAkshay S. Thomas
Akshay S. Thomas
TMTahreem A. Mir
Tahreem A. Mir
JKJane S. Kim
Jane S. Kim
FBFaith A. Birnbaum
Faith A. Birnbaum
SFSharon Fekrat
Sharon Fekrat

3 August 2023 in Cell Stem Cell
Verified
Journal Article
Closed access
ACAgnes S. Chao
Agnes S. Chao
PMPavle Matak
Pavle Matak
KPKelly Pegram
Kelly Pegram
JPJames Powers
James Powers
CHCollin Hutson
Collin Hutson
EBEric J. Benner
Eric J. Benner

1 March 2024 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
JPJames H. Powers
James H. Powers
MWMichael Wu
Michael Wu
MPMichelle Palumbo
Michelle Palumbo
CKChristopher J. Keary
Christopher J. Keary
CMChristopher J. McDougle
Christopher J. McDougle
RTRobyn P. Thom
Robyn P. Thom
Study Design: Retrospective case series. Objectives: The objective of this study was to provide naturalistic data on the use of guanfacine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in a clinically referred sample of youth with Down syndrome (DS). Methods: The medical records of children and adolescents with DS who received guanfacine for the treatment of ADHD from a multidisciplinary neurodevelopmental disorder clinic between September 1, 2011, and September 10, 2021, were reviewed. Demographic and clinical characteristics, guanfacine dose and treatment duration, and adverse effects were recorded. Clinical Global Impression Scale (CGI) scores for ADHD symptom severity (S) and improvement (I) were retrospectively assigned by a child and adolescent psychiatrist based on review of the clinic notes. Response to guanfacine was defined as completion of at least 12 weeks of treatment and a Clinical Global Impression Improvement subscale rating ≤2 (1 = "very much improved" or 2 = "much improved"). Results: Twenty-one patients were eligible for inclusion, of whom 17 (81%) completed at least 12 weeks of guanfacine. Ten of the 21 patients (48%; 95% confidence interval [CI]: 28%-68%) responded to treatment. The median time on guanfacine treatment covered by the clinic notes was 50.4 weeks, with a range of 0.3 weeks to 7.5 years. Thirteen patients (62%) remained on guanfacine at the time of their most recent clinic note. Nine patients had adverse events documented in their clinic notes (43%; 95% CI: 24%-63%), most commonly sleepiness (n = 7) and constipation (n = 2). Conclusion: About half of patients with DS responded to guanfacine for the treatment of ADHD and many tolerated long-term use. Study limitations primarily relate to the retrospective nature of the study and small sample size.

31 December 2019 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Open access
PDF file
JPJames H. Powers
James H. Powers
CWC. Ellis Wisely
C. Ellis Wisely
ASAnanth Sastry
Ananth Sastry
SFSharon Fekrat
Sharon Fekrat
Purpose: This report discusses a case of neovascular age-related macular degeneration with mixed serous pigment epithelial detachment (PED) that was unresponsive to antivascular endothelial growth injections but responded to the addition of intravitreal steroid injection. Methods: We report a case. Results: A 75-year-old woman with neovascular age-related macular degeneration developed a mixed serous PED in her right eye. Three monthly aflibercept (Eylea, Regeneron) treatments led to resolution of associated intraretinal fluid; however, the mixed serous and fibrovascular PED significantly increased in size. The addition of intravitreal dexamethasone (Ozurdex, Allergan) to monthly aflibercept led to prompt flattening of the PED. Three months later, the PED recurred despite continued administration of monthly aflibercept. Conclusions: This case supports a growing body of research that PEDs unresponsive to antivascular endothelial growth injections may respond to intravitreal steroid injections.